Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer May 15, ...
Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.
Key growth factors for KEYTRUDA include its unparalleled commercial scale, broad approval across multiple tumor types, strong uptake in early-stage therapies, and a robust clinical trial program.
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant ...
Complete response at 3 months was 79.6% (191/240), with duration-of-response estimates showing a gradual attrition over time ...
Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) Completed Financing ...
Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three MonthsFirst and Only FDA-Approved Medicine for Recurrent Low-Grade ...
Investigators conducted a meta-analysis of 4 randomized controlled trials including a total of more than 1000 men with prostate cancer.
The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.
Most second cancers detected within 6 yrs Irfan Tramboo Srinagar, May 15: A five-year study conducted by researchers at ...
Kyntra Bio, Inc. (NASDAQ: KYNB) Q1 2026 Earnings Call Transcript May 11, 2026 Kyntra Bio, Inc. misses on earnings expectations. Reported EPS is $-3.76 EPS, expectations were $-3.36.
Good afternoon, everyone, and thank you for joining us today to discuss Kyntra Bio, Inc.’s first quarter 2026 financial and business results. I am Gaia Vasiliver-Shamis from LifeSci Advisors. Joining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results